Form 4: Coherus BioSciences Director Acquires Stock Options

Kimberly Jo Tzoumakas, a director at Coherus BioSciences, acquired stock options for 112,000 shares on June 3, 2024.

Summary

• On June 3, 2024, Kimberly Jo Tzoumakas, a director of Coherus BioSciences, Inc. (CHRS), acquired stock options.
• The options grant the right to buy 112,000 shares of common stock at an exercise price of $1.76.
• The options vest 100% on June 3, 2025, one year after the grant date, contingent upon continued service with the issuer.
• The options expire on June 3, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither particularly positive nor negative on its own. The director's continued service requirement is a positive alignment of interests.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Future Outlook

The vesting of the options is contingent upon the reporting person's continued service with the company, aligning their interests with the long-term success of Coherus BioSciences.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year is fairly typical, aligning with industry norms for incentivizing long-term commitment.
• Comparing the size of the grant (112,000 shares) to similar companies would require analyzing their executive compensation packages and outstanding share counts.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, incentivizing actions that increase shareholder value.

Key Dates